StockData

Generate Biomedicines, Inc. (GENB) stock

GENBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$9.84−0.65 (-6.20%)

Close on Nov 17, 2026Market cap $1.26BP/E –Yield –

Generate Biomedicines cash

Cash and short-term investments held at the end of each period.

Generate Biomedicines's cash was $404.20M at Sep 30, 2026. For fiscal 2025 it was $221.50M.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$221.50M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$404.20M+241.0%
Q2 FY2026Jun 30, 2026$457.40M+196.5%
Q1 FY2026Mar 31, 2026$516.60M+134.2%
Q4 FY2025Dec 31, 2025$221.50M–
Q3 FY2025Sep 30, 2025$118.52M–
Q2 FY2025Jun 30, 2025$154.27M–
Q1 FY2025Mar 31, 2025$220.61M–

More Generate Biomedicines figures

See a number that looks wrong?